297 related articles for article (PubMed ID: 34232223)
1. The Role of Antisense Therapies Targeting Lipoprotein(a).
Plakogiannis R; Sorbera M; Fischetti B; Chen M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
[TBL] [Abstract][Full Text] [Related]
2. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
3. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) and Cardiovascular Diseases - Revisited.
Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
7. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
Tsimikas S
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
[TBL] [Abstract][Full Text] [Related]
9. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
10. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
Arnold SV; Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Alam S; Mues KE; Bhatt DL; Kosiborod M;
J Am Heart Assoc; 2021 Aug; 10(16):e020893. PubMed ID: 34369165
[TBL] [Abstract][Full Text] [Related]
11. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
Vuorio A; Watts GF; Kovanen PT
Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
[TBL] [Abstract][Full Text] [Related]
12. Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?
Vani A; Underberg JA
Clin Pharmacol Ther; 2018 Aug; 104(2):290-296. PubMed ID: 29882959
[TBL] [Abstract][Full Text] [Related]
13. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
14. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
Malick WA; Goonewardena SN; Koenig W; Rosenson RS
J Am Coll Cardiol; 2023 Apr; 81(16):1633-1645. PubMed ID: 37076218
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
16. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
[TBL] [Abstract][Full Text] [Related]
17. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
Tada H; Takamura M; Kawashiri MA
J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262
[TBL] [Abstract][Full Text] [Related]
19. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
Chan DC; Watts GF
Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
[TBL] [Abstract][Full Text] [Related]
20. Lipid-Lowering Agents.
Hegele RA; Tsimikas S
Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
